Upstart Akero continues its swoosh into NASH space with $70M windfall round

Upstart Akero continues its swoosh into NASH space with $70M windfall round

Source: 
Endpoints
snippet: 

Akero Therapeutics first swooshed onto the NASH stage with a drug in-licensed from Amgen, recruiting Gilead’s Andrew Cheng as CEO several months later and making a cross-country move to San Francisco. Now, it’s capping an eventful year with $70 million more to bankroll its Phase II work and scale the operations considerably.